Shots:

• Anima to receive ~ $120M up front- preclinical milestones and ~$1.1B as clinical and commercial milestones along with royalties on each product emerge under the collaboration
• Takeda gets an exclusive right to develop and commercialize the mRNA transational modulators and has a time limited option to expands the collaboration for three additional targets for which Anima will receive additional payments including ~$1.2B as milestones and royalties
• Anima will leverage its translation control therapeutics platform to discover novel mRNA translation modulators against the collaboration targets

 ­ Ref: GlobeNewswire | Image: GlobeNewswire